Advertisement
Dr. Worland joined Anadys in March 2001 as Chief Scientific Officer andmost recently served as President, Pharmaceuticals. Prior to joining theCompany, Dr. Worland was Vice President, Head of Antiviral Research, atAgouron Pharmaceuticals, a Pfizer Company and was also a Vice President atWarner-Lambert prior to the acquisition by Pfizer.
Advertisement
"We are pleased to appoint Steve as President and CEO," said George A.Scangos, Ph.D., Chairman of the Board. "Steve has been intimately involved inbuilding Anadys since its early days, knows the ANA773 and ANA598 programs indetail, and has the right skills and experience to lead the Company as itpursues the development of these two programs. The current focus for Anadysis to aggressively advance these projects, focus on execution and meet ourobjectives. Steve, who has evolved into a business and scientific leader, isperfectly positioned to lead the Company in pursuit of these goals. We remainon track to file an IND for ANA773 this year and an IND for ANA598 in thefirst half of 2008."
"I would like to thank Larry for his service and contributions to Anadysand wish him well with his future endeavors," added Dr. Scangos. "Larry hasplayed a key role at Anadys during the last year as the Company has evolved tofocus on its two development stage programs -- ANA598 for the treatment ofhepatitis C virus infection and ANA773 for the treatment of cancer."
"I remain impressed with the Anadys team and optimistic about theprojects," said Dr. Fritz. "Steve Worland is an extremely capable individualwho has all the skills to lead the Company forward, and I wish him and theCompany all the best."
About Anadys
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed toadvancing patient care by developing and commercializing novel small moleculemedicines for the treatment of hepatitis C virus (HCV) infection and cancer.The Company is developing ANA598, a small-molecule, non-nucleoside inhibitorof the NS5b polymerase for the treatment of HCV and ANA773, an oral TLR7agonist prodrug for cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical innature constitute "forward-looking statements." Such statements include, butare not limited to, references to the expected timing and planned developmentactivities for ANA598 and ANA773. Such forward-looking statements involveknown and unknown risks, uncertainties and other factors, which may causeAnadys' actual results to be materially different from historical results orfrom any results expressed or implied by such forward-looking statements. Forexample, the results of in vitro studies and initial clinical trials may notbe predictive of future results, and Anadys cannot provide any assurances thatany of its product candidates will not have unforeseen safety issues, willhave favorable results in future clinical trials or will receive regulatoryapproval. In addition, Anadys' results may be affected by risks related to itsagreements with Novartis and LG Life Sciences, competition from otherbiotechnology and pharmaceutical companies, its effectiveness at managing itsfinancial resources, its ability to successfully develop and market products,difficulties or delays in its pre-clinical studies or clinical trials,difficulties or delays in manufacturing its clinical trials materials, thescope and validity of
